Ask AI
ProCE Banner Activity

OptiTROP-Lung04: Phase III Trial of Sacituzumab Tirumotecan vs Chemotherapy in EGFRm NSCLC After Progression on EGFR-TKIs

Conference Coverage
Slideset

In the phase III OptiTROP-Lung04 study of patients with EGFR-mutated NSCLC and progression on EGFR-TKIs, the TROP2-directed antibody–drug conjugate sacituzumab tirumotecan significantly improved PFS and OS vs platinum-based chemotherapy.

Released: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly